The relevance of intrinsic subtype to clinicopathological features and prognosis in 4,266 Japanese women with breast cancer
Background Estrogen receptor (ER), progesterone receptor (PgR), and HER2 expression status in breast cancer function as prognostic and predictive factors that enable individualized treatment. Intrinsic subtype classification has also been performed based on these and other biological and prognostic...
Gespeichert in:
| Veröffentlicht in: | Breast cancer (Tokyo, Japan) Japan), 2011-10, Vol.18 (4), p.292-298 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 298 |
|---|---|
| container_issue | 4 |
| container_start_page | 292 |
| container_title | Breast cancer (Tokyo, Japan) |
| container_volume | 18 |
| creator | Shibuta, Kenji Ueo, Hiroaki Furusawa, Hidemi Komaki, Kansei Rai, Yoshiaki Sagara, Yoshiatsu Kamada, Yoshihiko Tamaki, Nobumitsu |
| description | Background
Estrogen receptor (ER), progesterone receptor (PgR), and HER2 expression status in breast cancer function as prognostic and predictive factors that enable individualized treatment. Intrinsic subtype classification has also been performed based on these and other biological and prognostic characteristics. However, clinical analysis of such subtypes in a large number of Japanese breast cancer patients has not yet been reported.
Methods
Between January 2003 and December 2007, 4,266 patients with primary breast cancer were registered. Four subtypes based on immunohistochemically evaluated ER/PgR/HER2 status, clinicopathological features, and prognosis were analyzed retrospectively.
Results
The following subtype distribution was observed: luminal A type (ER+ and/or PgR+, HER2−), 3,046 cases (71%); luminal B type (ER+ and/or PgR+, HER2+), 321 cases (8%); HER2 type (ER−, PgR−, HER2+), 398 cases (9%); and triple negative (TN) type (ER−, PgR−, HER2−), 501 cases (12%). The HER2+ subtypes (luminal B and HER2 types) had a significantly higher incidence of lymph node metastasis and lymphatic permeation, while the hormone receptor negative subtypes (HER2 and TN types) showed a significantly higher nuclear grade. Overall, patients with HER2-type and TN-type disease had a significantly poorer prognosis than other subtypes.
Conclusion
Intrinsic breast cancer subtypes are associated with clinicopathological features and prognosis in Japanese women. Long-term clinical observation of the relationship between each subtype and therapies used should provide useful information for selecting appropriately tailored treatments. |
| doi_str_mv | 10.1007/s12282-010-0209-6 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_900626009</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A712248548</galeid><sourcerecordid>A712248548</sourcerecordid><originalsourceid>FETCH-LOGICAL-c463t-b651bb66ed36efaa1865c9e3e59ce5fa39814e93d958ee1cb8c33580655bfee63</originalsourceid><addsrcrecordid>eNp9kU9rFTEUxQex2D_6AdxIwIWbTr1JJnmZZSnaWgpu6jpkMnfeS5lJxiRjKX55M0wVBJEsEpLfuTmcU1VvKVxQgN3HRBlTrAYKNTBoa_miOqFKQd0wzl-WM2-glkqq4-o0pQeAhu9AvqqOGYgdbSU7qX7eH5BEHPGH8RZJGIjzOTqfnCVp6fLTjCQHYkfnnQ2zyYcwhr2zZiQDmrxETMT4nswx7H1ILhU9ac6ZlOTWzMZjQvIYJvTk0eUD6SKalIldP4uvq6PBjAnfPO9n1bfPn-6vbuq7r9dfri7vattInutOCtp1UmLPJQ7GUCWFbZGjaC2KwfBW0QZb3rdCIVLbKcu5UCCF6AZEyc-qD9vcYvL7ginrySWL41jshSXpFkAyCdAW8v1G7s2I2vkh5GjsSuvLXQm7UaJRhbr4B1VWj1MJyePgyv1fAroJbAwpRRz0HN1k4pOmoNcm9dakLk3qtUm9mn73bHrpJuz_KH5XVwC2Aak8-T1G_RCW6EuQ_5n6C8R_qSw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>900626009</pqid></control><display><type>article</type><title>The relevance of intrinsic subtype to clinicopathological features and prognosis in 4,266 Japanese women with breast cancer</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Shibuta, Kenji ; Ueo, Hiroaki ; Furusawa, Hidemi ; Komaki, Kansei ; Rai, Yoshiaki ; Sagara, Yoshiatsu ; Kamada, Yoshihiko ; Tamaki, Nobumitsu</creator><creatorcontrib>Shibuta, Kenji ; Ueo, Hiroaki ; Furusawa, Hidemi ; Komaki, Kansei ; Rai, Yoshiaki ; Sagara, Yoshiatsu ; Kamada, Yoshihiko ; Tamaki, Nobumitsu</creatorcontrib><description>Background
Estrogen receptor (ER), progesterone receptor (PgR), and HER2 expression status in breast cancer function as prognostic and predictive factors that enable individualized treatment. Intrinsic subtype classification has also been performed based on these and other biological and prognostic characteristics. However, clinical analysis of such subtypes in a large number of Japanese breast cancer patients has not yet been reported.
Methods
Between January 2003 and December 2007, 4,266 patients with primary breast cancer were registered. Four subtypes based on immunohistochemically evaluated ER/PgR/HER2 status, clinicopathological features, and prognosis were analyzed retrospectively.
Results
The following subtype distribution was observed: luminal A type (ER+ and/or PgR+, HER2−), 3,046 cases (71%); luminal B type (ER+ and/or PgR+, HER2+), 321 cases (8%); HER2 type (ER−, PgR−, HER2+), 398 cases (9%); and triple negative (TN) type (ER−, PgR−, HER2−), 501 cases (12%). The HER2+ subtypes (luminal B and HER2 types) had a significantly higher incidence of lymph node metastasis and lymphatic permeation, while the hormone receptor negative subtypes (HER2 and TN types) showed a significantly higher nuclear grade. Overall, patients with HER2-type and TN-type disease had a significantly poorer prognosis than other subtypes.
Conclusion
Intrinsic breast cancer subtypes are associated with clinicopathological features and prognosis in Japanese women. Long-term clinical observation of the relationship between each subtype and therapies used should provide useful information for selecting appropriately tailored treatments.</description><identifier>ISSN: 1340-6868</identifier><identifier>EISSN: 1880-4233</identifier><identifier>DOI: 10.1007/s12282-010-0209-6</identifier><identifier>PMID: 20571962</identifier><language>eng</language><publisher>Japan: Springer Japan</publisher><subject>Adult ; Aged ; Analysis ; Biomarkers, Tumor - metabolism ; Breast cancer ; Breast Neoplasms - metabolism ; Breast Neoplasms - pathology ; Breast Neoplasms - therapy ; Cancer patients ; Cancer Research ; Disease-Free Survival ; Female ; Humans ; Immunohistochemistry ; Japan ; Medicine ; Medicine & Public Health ; Middle Aged ; Oncology ; Original Article ; Progesterone ; Prognosis ; Receptor, ErbB-2 - metabolism ; Receptors, Estrogen - metabolism ; Receptors, Progesterone - metabolism ; Retrospective Studies ; Surgery ; Surgical Oncology ; Women</subject><ispartof>Breast cancer (Tokyo, Japan), 2011-10, Vol.18 (4), p.292-298</ispartof><rights>The Japanese Breast Cancer Society 2010</rights><rights>COPYRIGHT 2011 Springer</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c463t-b651bb66ed36efaa1865c9e3e59ce5fa39814e93d958ee1cb8c33580655bfee63</citedby><cites>FETCH-LOGICAL-c463t-b651bb66ed36efaa1865c9e3e59ce5fa39814e93d958ee1cb8c33580655bfee63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12282-010-0209-6$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12282-010-0209-6$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,41467,42536,51298</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20571962$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shibuta, Kenji</creatorcontrib><creatorcontrib>Ueo, Hiroaki</creatorcontrib><creatorcontrib>Furusawa, Hidemi</creatorcontrib><creatorcontrib>Komaki, Kansei</creatorcontrib><creatorcontrib>Rai, Yoshiaki</creatorcontrib><creatorcontrib>Sagara, Yoshiatsu</creatorcontrib><creatorcontrib>Kamada, Yoshihiko</creatorcontrib><creatorcontrib>Tamaki, Nobumitsu</creatorcontrib><title>The relevance of intrinsic subtype to clinicopathological features and prognosis in 4,266 Japanese women with breast cancer</title><title>Breast cancer (Tokyo, Japan)</title><addtitle>Breast Cancer</addtitle><addtitle>Breast Cancer</addtitle><description>Background
Estrogen receptor (ER), progesterone receptor (PgR), and HER2 expression status in breast cancer function as prognostic and predictive factors that enable individualized treatment. Intrinsic subtype classification has also been performed based on these and other biological and prognostic characteristics. However, clinical analysis of such subtypes in a large number of Japanese breast cancer patients has not yet been reported.
Methods
Between January 2003 and December 2007, 4,266 patients with primary breast cancer were registered. Four subtypes based on immunohistochemically evaluated ER/PgR/HER2 status, clinicopathological features, and prognosis were analyzed retrospectively.
Results
The following subtype distribution was observed: luminal A type (ER+ and/or PgR+, HER2−), 3,046 cases (71%); luminal B type (ER+ and/or PgR+, HER2+), 321 cases (8%); HER2 type (ER−, PgR−, HER2+), 398 cases (9%); and triple negative (TN) type (ER−, PgR−, HER2−), 501 cases (12%). The HER2+ subtypes (luminal B and HER2 types) had a significantly higher incidence of lymph node metastasis and lymphatic permeation, while the hormone receptor negative subtypes (HER2 and TN types) showed a significantly higher nuclear grade. Overall, patients with HER2-type and TN-type disease had a significantly poorer prognosis than other subtypes.
Conclusion
Intrinsic breast cancer subtypes are associated with clinicopathological features and prognosis in Japanese women. Long-term clinical observation of the relationship between each subtype and therapies used should provide useful information for selecting appropriately tailored treatments.</description><subject>Adult</subject><subject>Aged</subject><subject>Analysis</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - metabolism</subject><subject>Breast Neoplasms - pathology</subject><subject>Breast Neoplasms - therapy</subject><subject>Cancer patients</subject><subject>Cancer Research</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Japan</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Progesterone</subject><subject>Prognosis</subject><subject>Receptor, ErbB-2 - metabolism</subject><subject>Receptors, Estrogen - metabolism</subject><subject>Receptors, Progesterone - metabolism</subject><subject>Retrospective Studies</subject><subject>Surgery</subject><subject>Surgical Oncology</subject><subject>Women</subject><issn>1340-6868</issn><issn>1880-4233</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU9rFTEUxQex2D_6AdxIwIWbTr1JJnmZZSnaWgpu6jpkMnfeS5lJxiRjKX55M0wVBJEsEpLfuTmcU1VvKVxQgN3HRBlTrAYKNTBoa_miOqFKQd0wzl-WM2-glkqq4-o0pQeAhu9AvqqOGYgdbSU7qX7eH5BEHPGH8RZJGIjzOTqfnCVp6fLTjCQHYkfnnQ2zyYcwhr2zZiQDmrxETMT4nswx7H1ILhU9ac6ZlOTWzMZjQvIYJvTk0eUD6SKalIldP4uvq6PBjAnfPO9n1bfPn-6vbuq7r9dfri7vattInutOCtp1UmLPJQ7GUCWFbZGjaC2KwfBW0QZb3rdCIVLbKcu5UCCF6AZEyc-qD9vcYvL7ginrySWL41jshSXpFkAyCdAW8v1G7s2I2vkh5GjsSuvLXQm7UaJRhbr4B1VWj1MJyePgyv1fAroJbAwpRRz0HN1k4pOmoNcm9dakLk3qtUm9mn73bHrpJuz_KH5XVwC2Aak8-T1G_RCW6EuQ_5n6C8R_qSw</recordid><startdate>20111001</startdate><enddate>20111001</enddate><creator>Shibuta, Kenji</creator><creator>Ueo, Hiroaki</creator><creator>Furusawa, Hidemi</creator><creator>Komaki, Kansei</creator><creator>Rai, Yoshiaki</creator><creator>Sagara, Yoshiatsu</creator><creator>Kamada, Yoshihiko</creator><creator>Tamaki, Nobumitsu</creator><general>Springer Japan</general><general>Springer</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20111001</creationdate><title>The relevance of intrinsic subtype to clinicopathological features and prognosis in 4,266 Japanese women with breast cancer</title><author>Shibuta, Kenji ; Ueo, Hiroaki ; Furusawa, Hidemi ; Komaki, Kansei ; Rai, Yoshiaki ; Sagara, Yoshiatsu ; Kamada, Yoshihiko ; Tamaki, Nobumitsu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c463t-b651bb66ed36efaa1865c9e3e59ce5fa39814e93d958ee1cb8c33580655bfee63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Analysis</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - metabolism</topic><topic>Breast Neoplasms - pathology</topic><topic>Breast Neoplasms - therapy</topic><topic>Cancer patients</topic><topic>Cancer Research</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Japan</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Progesterone</topic><topic>Prognosis</topic><topic>Receptor, ErbB-2 - metabolism</topic><topic>Receptors, Estrogen - metabolism</topic><topic>Receptors, Progesterone - metabolism</topic><topic>Retrospective Studies</topic><topic>Surgery</topic><topic>Surgical Oncology</topic><topic>Women</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shibuta, Kenji</creatorcontrib><creatorcontrib>Ueo, Hiroaki</creatorcontrib><creatorcontrib>Furusawa, Hidemi</creatorcontrib><creatorcontrib>Komaki, Kansei</creatorcontrib><creatorcontrib>Rai, Yoshiaki</creatorcontrib><creatorcontrib>Sagara, Yoshiatsu</creatorcontrib><creatorcontrib>Kamada, Yoshihiko</creatorcontrib><creatorcontrib>Tamaki, Nobumitsu</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Breast cancer (Tokyo, Japan)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shibuta, Kenji</au><au>Ueo, Hiroaki</au><au>Furusawa, Hidemi</au><au>Komaki, Kansei</au><au>Rai, Yoshiaki</au><au>Sagara, Yoshiatsu</au><au>Kamada, Yoshihiko</au><au>Tamaki, Nobumitsu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The relevance of intrinsic subtype to clinicopathological features and prognosis in 4,266 Japanese women with breast cancer</atitle><jtitle>Breast cancer (Tokyo, Japan)</jtitle><stitle>Breast Cancer</stitle><addtitle>Breast Cancer</addtitle><date>2011-10-01</date><risdate>2011</risdate><volume>18</volume><issue>4</issue><spage>292</spage><epage>298</epage><pages>292-298</pages><issn>1340-6868</issn><eissn>1880-4233</eissn><abstract>Background
Estrogen receptor (ER), progesterone receptor (PgR), and HER2 expression status in breast cancer function as prognostic and predictive factors that enable individualized treatment. Intrinsic subtype classification has also been performed based on these and other biological and prognostic characteristics. However, clinical analysis of such subtypes in a large number of Japanese breast cancer patients has not yet been reported.
Methods
Between January 2003 and December 2007, 4,266 patients with primary breast cancer were registered. Four subtypes based on immunohistochemically evaluated ER/PgR/HER2 status, clinicopathological features, and prognosis were analyzed retrospectively.
Results
The following subtype distribution was observed: luminal A type (ER+ and/or PgR+, HER2−), 3,046 cases (71%); luminal B type (ER+ and/or PgR+, HER2+), 321 cases (8%); HER2 type (ER−, PgR−, HER2+), 398 cases (9%); and triple negative (TN) type (ER−, PgR−, HER2−), 501 cases (12%). The HER2+ subtypes (luminal B and HER2 types) had a significantly higher incidence of lymph node metastasis and lymphatic permeation, while the hormone receptor negative subtypes (HER2 and TN types) showed a significantly higher nuclear grade. Overall, patients with HER2-type and TN-type disease had a significantly poorer prognosis than other subtypes.
Conclusion
Intrinsic breast cancer subtypes are associated with clinicopathological features and prognosis in Japanese women. Long-term clinical observation of the relationship between each subtype and therapies used should provide useful information for selecting appropriately tailored treatments.</abstract><cop>Japan</cop><pub>Springer Japan</pub><pmid>20571962</pmid><doi>10.1007/s12282-010-0209-6</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1340-6868 |
| ispartof | Breast cancer (Tokyo, Japan), 2011-10, Vol.18 (4), p.292-298 |
| issn | 1340-6868 1880-4233 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_900626009 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Adult Aged Analysis Biomarkers, Tumor - metabolism Breast cancer Breast Neoplasms - metabolism Breast Neoplasms - pathology Breast Neoplasms - therapy Cancer patients Cancer Research Disease-Free Survival Female Humans Immunohistochemistry Japan Medicine Medicine & Public Health Middle Aged Oncology Original Article Progesterone Prognosis Receptor, ErbB-2 - metabolism Receptors, Estrogen - metabolism Receptors, Progesterone - metabolism Retrospective Studies Surgery Surgical Oncology Women |
| title | The relevance of intrinsic subtype to clinicopathological features and prognosis in 4,266 Japanese women with breast cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T19%3A19%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20relevance%20of%20intrinsic%20subtype%20to%20clinicopathological%20features%20and%20prognosis%20in%204,266%20Japanese%20women%20with%20breast%20cancer&rft.jtitle=Breast%20cancer%20(Tokyo,%20Japan)&rft.au=Shibuta,%20Kenji&rft.date=2011-10-01&rft.volume=18&rft.issue=4&rft.spage=292&rft.epage=298&rft.pages=292-298&rft.issn=1340-6868&rft.eissn=1880-4233&rft_id=info:doi/10.1007/s12282-010-0209-6&rft_dat=%3Cgale_proqu%3EA712248548%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=900626009&rft_id=info:pmid/20571962&rft_galeid=A712248548&rfr_iscdi=true |